Skip to Content
Søk Menu

Vaccinating Against Mutated RAS in Multiple Myeloma

At EHA 2024, Hanne Norseth, MD, PhD student, Oslo Myeloma Center, Norway, presents a study that aims to evaluate vaccinating against mutated RAS in multiple myeloma. In this MEDtalk, Hanne Norseth presents the tentative data of the ongoing study.
Hanne Norseth

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

Fredrik Schjesvold

The Trispecific Antibody SAR’257 Discontinued After Phase 1 Findings

/ Fredrik Schjesvold
ASH24Myelom Play the Video 03:29

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ BestPractice Nordic
EHA24Myelom

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymfom

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
CLLEHA24

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24

Using PRO Data to Assess Treatment Readiness in Multiple Myeloma

/ Tine Rosenberg / Thomas Lund / Jannie Kirkegaard
Myelom

New Data from EHA Shared and Discussed at Danish Evening

/ Jan Andreasen
EHA24
Fredrik Schjesvold

Choice of Selinexor in the Treatment of Myeloma

/ Fredrik Schjesvold
Myelom Play the Video 7:09

The Missing Link of Light Chain Smoldering Multiple Myeloma

/ Sofie Pohl
Myelom
Back to top